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contains one intrauterine and two vaginal catheters. The presence of 
an RTT during the vaginal impression is essential as support to the 
radiation oncologist. Based on the tumour topography representation, 
the RTT is able to manufacture a personalized mould adapted to the 
patient anatomy. The catheters positions are placed according to the 
physician recommendations. 
Before each treatment, the RTT performs quality controls on the 
afterloader. These controls, made under physicist responsibility, 
include all safety tests, verification of source positioning and 
agreement between air kerma rate calculated by the afterloader at 
the date of treatment for the source and the one measured at the 
date of calibration. 
In the operating room, the RTT checks the patient’s identity and is in 
charge of the patient installation. She prepares the medico-surgical 
instrumentation table and assists the radiation oncologist during the 
procedure. At the end of the implantation, she fills the technical 
documentation and gives it to nurses.  
Once the implantation is performed, the patient is transferred to the 
MRI scanner. With the help of a physician, the RTT inserts MRI 
compatible dummy sources into the catheters allowing a visualization 
of the intrauterine and vaginal positions of the sources. The 
delineation and the dosimetry are realised on MRI images. In this 
optimized 3D dosimetry, the RTT takes part in every step of the 
treatment. She creates the patient file in the treatment planning 
system (TPS),imports, checks the MRI images, and reconstructs the 
cervix applicator. Following the dosimetry validation, she records 
treatment parameters on a register and informs the patient on her 
treatment before it starts. 
In conclusion we have shown that the RTT is involved in every step of 
the cervix BT treatment. Her role is crucial in the treatment workflow 
and needs specifics skills to be accomplished.  In addition to 
versatility, the RTT needs a rigor, thoroughness, empathy and 
patience.  
   
 SYMPOSIUM: LYMPHOMA: TO IRRADIATE OR NOT TO 
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The question is whether PET response-adapted strategies can be 
devised to deliver radiation treatments to a selected group of 
patients. The backdrop of this persistent and sometimes emotional 
quest is complex but can be summarized as follows: first, combined 
modality treatments are superior to chemotherapy alone in terms of 
overall and progression-free survival, as demonstrated by a recent 
meta-analysis (1). Second, chemotherapy is very efficacious. Third, 
radiation treatments be get late complications such as second tumors 
and cardiovascular diseases. Fourth, the late effects of ABVD might 
have been grossly underestimated (2). PET response-adapted 
strategies can be implemented if PET predictive values are highly 
significant and reliable. Preliminary conclusions can be obtained from 
a small number of non randomized studies after completion of 
planned treatments. The negative predictive value (NPV) for the 
intermediary and end of treatment PET assessments was excellent (> 
95%). In contrast, the positive predictive value (PPV) was extremely 
low (15%-20%) and therefore systematic biopsies are always highly 
recommended to confirm the diagnosis. As, in all likelihood,the role 
of radiation therapy in advanced Hodgkin lymphoma will remain 
extremely reduced, we will focus on ongoing trials in early-stage 
Hodgkin lymphoma. Currently, there are 4 randomized trials and one 
non-randomized study. The relatively small Vancouver non-
randomized study suggested that radiotherapy could be avoided in 
approximately 80% of the patients with a negative PET after 2 ABVD 
cycles. Among the randomized trials, very favorable Hodgkin 
lymphoma patients were entered in 2 of them (mostly IA and IIA: 
GHSG and the UK Rapid trial). In two others (EORTC-LYSA-FIL H10, 
Euronet-PHLC-C1), all early stages were included. The preliminary 
results of the UK Rapid trial suggest that radiotherapy was not 
necessary in patients with a negative PET scan after 2 to 3 cycles of 
ABVD (75% of the patients). On the other hand, an interim analysis of 
the much larger H10 trial demonstrated that PET-negative patients 
after 2 ABVD cycles had a significantly higher risk of local recurrence 
or progression. The experimental arm with PET-negative patients was 
prematurely closed for further accrual. The very preliminary results of 
the ongoing Euronet trial, suggest that radiation treatments were not 
performed in a substantial number of PET-negative patients (only 40% 
of the French patients received radiation therapy: 26%, 41%, and 50% 
in the TG1, TG2, and TG3 groups respectively). 
Conclusions. Very preliminary results seem to suggest that an early 
PET response might provide a reliable basis for individualized 
response-adapted treatment strategies. However, the final results of 
the ongoing randomized trials should be awaited before drawing 
definite conclusions that may be applicable in clinical practice. 
Moreover, it must be emphasized that difficulties remain: the still 
persistent variability of PET assessment and the absence of a clear 
understanding of the underlying biological mechanisms of PET avidity. 
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Radiotherapy (RT) is the most effective single modality for local 
control of non Hodgkin lymphoma (NHL), and it is an important 
component of the treatment of many patients. The previously applied 
wide field and involved field techniques are no longer relevant, and 
have been replaced by defined volumes based on modern imaging and 
the ICRU concepts, the so-called involved site RT. Moreover, there is 
increasing evidence that the RT doses used in the past are higher than 
necessary for disease control. The goal of modern smaller field 
radiotherapy is to reduce both treatment volume and treatment dose 
whilst maintaining efficacy and minimising acute and late sequelae. 
B-cell lymphomas constitute 85-90 % of lymphomas in adults. The 
large majority expresses CD20 antigen. The development of anti-CD20 
antibodies, first Rituximab approved in 1997, significantly improved 
treatment results when added to standard chemotherapy for patients 
with advanced disease. The question is now if the role of RT in B-cell 
lymphomas has changed. 
Diffuse large B-cell lymphoma (DLBCL) is the most common 
aggressive lymphoma. For stage I-II patients without bulk or elevated 
LDH, standard treatment based on somewhat conflicting randomized 
trials was brief chemotherapy (3 cycles of CHOP) followed by IFRT. No 
randomized trial is available using R-CHOP, but retrospective analyses 
indicate that RT improves outcome also in this setting. For patients 
with risk factors 3 cycles of R-CHOP may not be enough. A positive 
PET-scan after R-CHOP has a low predictive value, and most PET+ 
cases achieve complete remission (CR) after RT. For advanced disease 
earlier studies showed benefit from RT in patients achieving a CR in 
some studies but not in others, whereas patients achieving only partial 
remission (PR) benefit from RT to residual masses. However, recent 
randomized studies in patients treated with Rituximab indicate that 
RT to initial bulk or extranodal disease, even in CR patients, improves 
outcome. Randomized evidence indicates that 30 Gy is a sufficient 
dose, at least in CR patients.  
Follicular lymphoma (FL) grade 1-2 is the most common indolent 
lymphoma. In early stage disease RT is still the only proven way for 
potential cure. Standard treatment is RT alone, and randomized 
evidence indicates that 24 Gy is a sufficient dose. Unfortunately, this 
treatment seems to be underused. For patients with advanced 
disease, if treatment is indicated, Rituximab with or without 
chemotherapy is given, but has not been shown to be curative. Low 
dose (2 Gy x 2) RT is an effective palliative treatment for locally 
symptomatic disease. 
Marginal zone lymphomas are indolent B-cell lymphomas, most often 
extranodal and localized. RT (24-30 Gy) is curative in the majority of 
localized cases, and is the preferred treatment (except for H. pylori 
positive gastric). Rituximab may be used if RT is contraindicated. 
Advanced disease is uncommon, no curative treatment exists, treated 
like FL. 
Mantle cell lymphomas are B-cell lymphomas with an aggressive 
behaviour. Very rarely these lymphomas are localized, and RT may be 
curative. No curative systemic treatment exists, and although 
Rituximab improves response rate and time to treatment failure it has 
little impact on survival. Advanced disease is incurable, but local 
palliative RT can be very effective. 
Primary cutaneous B-cell lymphomas are treated with local RT if 
solitary or regional. Only the aggressive type, DLBCL leg type, is also 
treated systemically (R-CHOP) for patients who can tolerate it. 
Patients with generalized disease are treated palliatively with 
Rituximab containing regimens, and local RT is given for palliation of 
symptoms.  
T-cell lymphomas are CD20 negative, and treatment is not influenced 
by the introduction of Rituximab. Most T-cell lymphomas present as 
advanced disease, RT has no role in the treatment except for 
palliation, and prognosis is poor. Exceptions are NK/T-cell lymphomas, 
cutaneous anaplastic large cell lymphomas, and mycosis fungoides, 
where RT is an important part of treatment.  
